The present invention relates to a Lactobacillus lactis CKDB001 strain, and a composition for the prevention or treatment of non-alcoholic fatty liver comprising same. When the composition of the present invention is ingested, the composition has the effect of ameliorating high-fat diet-induced fatty cirrhosis and inflammations caused thereby, and thus the composition of the present invention can be effectively used as a preparation for ameliorating or treating non-alcoholic fatty cirrhosis and steatohepatitis.

Provided are an astragalus membranaceus fermentation product and a method of producing the astragalus membranaceus fermentation product, in which a lactic acid bacteria starter or a yeast starter proliferated and cultured in a medium is inoculated into a mixture, in which astragalus membranaceus, sugar, and water are mixed, to be fermented, and then a pH of a fermentation material obtained by fermenting is measured, and the fermentation material having a pH within a predetermined range is filtered and dried to obtain the astragalus membranaceus fermentation product.

The invention relates to acetylcholine-producing microorganisms for use in the prevention and/or treatment of intestinal diseases, and/or reduction of risks of intestinal diseases, and/or improvement of intestinal health as well as promoting healthy gut flora. The acetylcholine-producing microorganisms may be provided as a pharmaceutical dosage form or as additive to functional food or food supplemental products. Also encompassed is a method for the production of acetylcholine by use of Lactobacilli. Further the invention refers to microbially produced acetylcholine for use in the treatment and/or prevention of intestinal diseases.

The invention relates to a probiotic strain selected from Lactobacillus reuteri V340 with accession number CECT and Bifidobacterium breve BT820 with accession number CECT 8606, or a variant of said probiotic strain having cholesterol-absorbing capacity, and to methods and therapeutic uses thereof. The invention also relates to compositions, pharmaceutical compositions, feeds or nutritional products comprising a probiotic strain selected from Lactobacillus reuteri V3401 with accession number CECT 8605 and Bifidobacterium breve BT820 with accession number CECT 8606, or a variant of said probiotic strain having cholesterol-absorbing capacity.

Provided is Lactobacillus curvatus SPC-SNU 70-3 (KCTC 12778BP) which is novel natural Korean lactic acid bacteria isolated from traditional Korean nuruk.

The present invention discloses Lactobacillus sakei for alleviating allergy and a preparation method thereof, and particularly Lactobacillus sakei for alleviating wheat-dependent, exercise-induced anaphylaxis (WDEIA). The Lactobacillus sakei is classified and named as Lactobacillus sakei. The Lactobacillus sakei has been preserved in China Center for Type Culture Collection since Apr. 12, 2003, with a preservation number of CCTCC DB 20082413. The Lactobacillus sakei can regulate the immune function of a human body to prevent/treat WDEIA by reducing the contents of specific IgE and histamine in serum of WDEIA patients.

Provided herein are pharmaceutical compositions comprising a bacterial consortium and one or more pharmaceutically acceptable excipients. Such pharmaceutical compositions can be orally administered to a subject for prevention and/or treatment of dysbiosis, dysbiosis associated conditions, inflammation, and autoimmune diseases.

The subject invention provides compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Preferred embodiments of the invention provide pharmaceutical and cosmetic compositions, and the methods of using the same, comprising a strain of Lactobacillus fermentum bacterium, or bioactive extracts thereof, derived from human microbiota and capable of growing in biofilm phenotype.

Described herein are methods and compositions for the use of treating and/or preventing vaginal bacterial infection and promoting healthy vaginal flora. Aspects of the invention relate to administering to a subject in need thereof a composition comprising a bacterial mixture of L. crispatus, L. gasseri, and L. jensenii.

There is provided a salt-tolerant Lactobacillus having high foodstuff suitability, being easily produced, and having an immunostimulatory action. Salt-tolerant Lactobacillus having an immunostimulatory action with viability and activation potency of B cells.